Korean J Psychopharmacol.  2001 Jun;12(2):99-105.

The Therapeutic Application of Atypical Antipsychotics for Treatment-Resistant Obsessive Compulsive Disorder

• Kim SW
• Yu BH

Abstract

Although serotonin reuptake inhibitors (SRIs) are the primary therapeutic drugs for obsessive compulsive disorder (OCD), as many as 40% (up to 60%) of OCD patients do not show an adequate response to these drugs. SRI-refractory patients with OCD may have abnormalities in their central dopaminergic system as well as serotonergic system. The combination therapy with SRIs and antipsychotic drugs is considered to be effective especially for treatment-refractory OCD patients who have comorbid tic disorders or schizotypal personality disorder. Recently, the augmentation of atypical antipsychotics has been suggested to be effective in treating SRI-refractory OCD patients, and risperidone and olanzapine could be promising drugs for SRI-refractory OCD patients. We reviewed recent literatures regarding the clinical efficacy of atypical antipsychotics for treatment-refractory OCD patients.

Keyword

Obsessive-compulsive disorder; Atypical antipsychotics; Serotonin reuptake inhibitors

MeSH Terms

Antipsychotic Agents*
Humans
Obsessive-Compulsive Disorder*
Risperidone
Schizotypal Personality Disorder
Serotonin Uptake Inhibitors
Tic Disorders
Antipsychotic Agents
Risperidone
Serotonin Uptake Inhibitors